Abstract
- The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.
| Translated title of the contribution | Treatment of patients with stage III non-small cell lung cancer: Concurrent high-dose chemotherapy and radiotherapy |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 2714-2717 |
| Number of pages | 4 |
| Journal | Nederlands Tijdschrift voor Geneeskunde |
| Volume | 152 |
| Issue number | 50 |
| Publication status | Published - 13 Dec 2008 |
Cite this
}
Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III : Gelijktijdig hooggedoseerde chemotherapie en radiotherapie. / El Sharouni, S. Y.; Aerts, J. G.J.V.; Senan, S.; De Ruysscher, D. K.M.; Groen, H. J.M.; Paul, M. A.; Smit, E. F.; Vonk, E. J.A.; Verhagen, A. F.; Schramel, F. M.N.H.
In: Nederlands Tijdschrift voor Geneeskunde, Vol. 152, No. 50, 13.12.2008, p. 2714-2717.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III
T2 - Gelijktijdig hooggedoseerde chemotherapie en radiotherapie
AU - El Sharouni, S. Y.
AU - Aerts, J. G.J.V.
AU - Senan, S.
AU - De Ruysscher, D. K.M.
AU - Groen, H. J.M.
AU - Paul, M. A.
AU - Smit, E. F.
AU - Vonk, E. J.A.
AU - Verhagen, A. F.
AU - Schramel, F. M.N.H.
PY - 2008/12/13
Y1 - 2008/12/13
N2 - - The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.
AB - - The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years. - Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting of chemotherapy and radiotherapy. These can be administered sequentially or concurrently. - It has been shown recently that concurrent chemoradiotherapy gives a survival advantage in comparison with sequential chemoradiotherapy. - Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer. - A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given. - Surgery is possible for a selected group of patients, provided a complete objective mediastinal response has been achieved after chemoradiotherapy and a complete resection appears to be technically feasible. It is recommended to apply this treatment in a research setting. - High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.
UR - http://www.scopus.com/inward/record.url?scp=57949105437&partnerID=8YFLogxK
M3 - Review article
VL - 152
SP - 2714
EP - 2717
JO - Nederlands Tijdschrift voor Geneeskunde
JF - Nederlands Tijdschrift voor Geneeskunde
SN - 0028-2162
IS - 50
ER -